FDA Amendments Act’s One-Year Anniversary: For Better Or Worse
Executive Summary
At the one-year anniversary of the FDA Amendments Act, the agency's record is mixed in meeting its increased responsibilities and authorities the law requires
You may also be interested in...
The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months
FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on roughly one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March.
The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months
FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on roughly one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March.
The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months
FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March